摘要
目的:研究HIF-2α、HSP90和VEGF在人肾透明细胞癌中的表达,分析肾透明癌中HIF-2α、HSP90和VEGF表达的相关性及其与肾癌临床病理、预后之间的关系。
方法:应用免疫组织化学S-P法检测60例肾透明细胞癌、20例癌旁组织及5例正常肾组织中HIF-2α、HSP90和VEGF的表达,比较HSP90、HIF-2α及VEGF表达关系及其与肾癌的病理分级、临床分期等临床病理之间的关系,根据随访资料探讨上述三者与肾细胞癌患者预后的关系。
结果:HIF-2α、HSP90及VEGF在肾癌标本中的表达明显高于对照组,差异有统计学意义(P<0.05),与肾癌的分期、肿瘤大小、淋巴转移及局部浸润有关;三个指标之间,两两呈显著正相关。三者与肾细胞癌患者生存期之间关系分析提示HSP90阴性组生存率有高于阳性组的趋势,HIF-2α、VEGF阳性组病例的预后显著差于阴性组,差异有统计学意义。
结论:HIF-2α、HSP90和VEGF在肾癌中高表达并与肾癌的临床分期、肿瘤大小密切相关,且三指标间的表达两两呈显著正相关。HIF-2α和VEGF是影响肾细胞癌预后的独立因素。联合检测HIF-2α、HSP90和VEGF可作为判断肾癌病理生物学行为的指标,有助于提高对肾癌侵袭转移能力的评估。
Objective: To investigate the expression of the HSP90、HIF-2αand vascular endothelial growth factor (VEGF) in renal clear cell carcinoma(RCC). Analyze the relationship among these protein and the clinicopathologic features of human renal cell carcinoma. To explore the role of HSP90、HIF-2αand VEGF in the outcome of renal cell carcinoma.
Methods: Formalin-fixed paraffin embedded tissues from 60 cases of RCC and 20 cases of normal renal tissues which were closely adjacent to carcinoma and 5 cases of normal renal tissues were evaluated for HSP90、HIF-2αand VEGF protein expression by immunnhistochemical S-P method. Analyze the significance of them with the clinicopathologic features and outcome in human renal cell carcinoma.
Results: The positive incidence of expressions HSP90、HIF-2αand VEGF protein in RCC were prominently higher than control group, and significant correlations were observed among them. The expressions of HSP90、HIF-2αand VEGF were closely related with the stage, LN metastasis and the size of tumor of renal cell carcinoma. The survival rate is slightly higher in renal cell carcinoma, which has low expression of HSP90. The overall survival rate is higher in renal cell carcinoma, which has low expression of HIF-2αand VEGF.
Conclusion: Increased expression of HIF-2α、HSP90 and VEGF are markedly correlated with clinical stage and the size of tumor, and HIF-2αpositively correlated with the expression of HSP90 and VEGF .Combined detection of HSP90、HIF-2αand VEGF maybe helpful to evaluate prognosis and infiltrative capability of RCC.
引文
1. Janzen NK, Kim HL, Figlin RA, et a1. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J]. Urol Clin North Am, 2003, 30(4):843-852.
2. Jemal A, Clegg LX, Ward E, et a1. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival [J]. Cancer, 2004, 101(1):3-27.
3.全国肿瘤防治研究办公室,卫生部卫生统计信息中心.中国试点市、县恶性肿瘤的发病与死亡(1993-1997)[M].第2卷,北京:中国医药科技出版社,2002, 271-297.
4. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patiens with stageⅣrenal carcinoma. Clin Cancer Res, 2004, 10:6342S-6S.
5. Stephan S, John EB, Adlakha K, et al. Classification of renal cell carcinoma: workgroup No 3. Cancer, 1997, 80:987-989.
6. Yan Q, Kamura T, Cai Y, et al. Identification of Elongin C and Skp1 sequences that determine Cullin selection [J]. J Biol Chem, 2004, 279(41):43019-43026.
7. Gunaratnam L, Morley M, Franovic A, et a1. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL (-/-) renal cell carcinoma cells. J Biol Chem. 2003, 278:44966-4974.
8. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res, 2002, 62:2957-2961.
9. Kamal A, Thao L, Sensintafar J, et a1. A high affinity conformation of HSP90 confers tumour selectivity on HSP90 inhibitors [J]. Nature, 2003, 425(6956):407-410.
10. Hua zhong, Angelo M, peet DJ, et al. Regulation of geno expression by the hypoxia- inducible factor 1alpha in Common human Cancer and their metastasis. Cancer Res, 1999, 59(22):5830-5835.
11. Giatromanolaki A, koukourakis MI, Sivridis E, et al. relation of hypoxia inducible factor 1αand 2αin operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer, 2001, 85(6):881-890.
12. Birner P, Schindle Molermair A, et al, Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavourable prognosis in early-stage invasive cervical cancer. Cancer Res, 2000, 60(17):4693-4696.
13. Linehan WH, Walther MM, Zbar B. The genetic basis of Cancer of the kidney, J Urol. 2003 Dec; 170(6 p+1):2163-2172.
14. Gatnra JR, Tory K, Weny Y. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
15. Herman JG, Latif F, weng Y, et al.Silencing of the VHL tumor-suppressor gene by DNA methylationin in renal carcinoma. Proc Natl Acad Sci USA. 1994 oct 11:9 (21):9700- 9704.
16. Heinzer H, Huland H. Treatment of metastatic renal cell carcinoma. Value of immmunotherapy comprared with surgery of metastases. Urology A. 2000 Jul; 39(4): 356-361.
17. Pugh CW, Raticliffe PJ, regulation of angiogenesis by hypoxia: role of the HIFsystem. Nat Med. 2003 Jun; 9(6):677-684.
18. Kaelin, W.G. The von Hippel-Lindau gene, kindney and oxgen sellsing.J. AM Soc, Nephrol.2003, 14:2703-2711.
19. Ohh M, Psrk cw, Ivan M, et al. Ubiquitination of hypoxia-Inducible factor repairs direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000 Jul; 2(7):421-427.
20. Krek, W, VHL takes HIF’S breath way. Nat Cell Biol 2000 Jul; 2(7): E 121-123.
21. Lǒfstedt T, Fred lund E, Holmquist-Mengelbiex L, et al. Hypoxia inducible factor-2 alpha in cancer cell cycle, 2007, 6(8):919-926.
22. Monnoto RI, Regulation of the heat shock transcriphtional response: Cross talk between a family of heat shock factors, Molecular chaperones and negative regulators.Genes Dew. 1998 Eec 15; 12(24):3788-3796.
23. Jolly C, Morimoto RI Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 2000 Oct 4; 92(19):1564-1572.
24. Pratt WB, Toft Do, Regulation of signaling proterin fuction and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Bid Med. 2003 Feb 228(2):111-133.
25. Isaacs Js, Xu W, Necker SL, heat shock protein 90 as a, particular target for cancer therapeutics. Cander Cell. 2003 Mar; 3(3):213-217.
26. Linehan WM, Vassel; J, Sriniva san R, et al. Genetic basis of cancer of the kidney: disease-spcific approaches to therapy, clin Cancer Res, 2004 sep 15:10(18 pt 2): 6282s-6289s.
27. Kurahashi T, Miyake H, Hara I. et al. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. JU rol. 2007, 177(2):757-761.
28. Castle PE, Ashfaq R, Ansari F. et al. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett 2005, 229(2): 245-252.
29. Zhong L, Peng X, Hidalgo GE, et al. Antibodies to HSP70 and HSP90 in serum in non- small cell lung cancer patients. Cancer Detect Perv. 2003, 27(4):285-290.
30. Zuo DS, Dai J, Bo AH. et a1. Significance of expression of heat shock protein 90alpha in human gastric cancer. World J Gastroenterol 2003. 9(11):2616-2618.
31. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal Cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res, 2002, 62:2957-2961.
32. Choi KS, Bae MK, Jeong JW, et al. Hypoxia-inducible angiogenesis during carcinogenssis [J]. J Bioche Mole Bio, 2003, 36:504-507.
33. Shinojima T, Oga M, Takayanagi A, et al. Renal cancer cells lacking hypoxia inducible factor(HIF)-1 alpha expression maintain vascular endothe growth factor expression through HIF-2 alpha, Carcinogenesis, 2007, 28(3):529-536.
34. Morishita C, Jin E, Kikuchi M, et al. Angiogenic swiching in the aldeolar capillaries in primary lung adenocarcinoma and squamous cell carcinoma[J]. Nippon Med Sch, 2007, 74(5):3344-354.
35.吕厚君.肝癌组织中VEGF的表达与淋巴结微转移的关系[J].肿瘤基础与临床2008, 21(4):3483-49.
36.王海燕,陈贵安,张波.血管内皮生长因子及其受体在子宫内膜癌中的表达.中华病理学杂志,2002, 31(5):391-395.
37. Maede K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinomas. Cancer, 1996, 77(5):858-876.
38. Oshika Y. Nakamura T.et al. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expressions in non-small cell lung cancer (NSCLC). European journal of Cancer, 2000, 36(18):2390-2396.
39. Raval RR, Lau kw, TARAN MG, et al. Contrasting properties of hypoxia-inducible factor 1(HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma, Mol cell Biol, 2005, 25(13):5675-5686.
40. Zimmer M, Doucette D, Siddigui: N, et al. inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumours. Mol cancer Res, 2004, 2(2):89- 95.
41. Ratcliffe PJ. HIF-1αHIF-2α: working alone or together in hypoxia. J clin Invest, 2007, 117(4):862-865.
42. Favier J, Kempf H, Corvol P, et al. Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Dev Dyn, 2001, 222(3):377-388.
43. Akeno N, Czyzyk-Krzeska MF, Gross TS, et al. Hypoxia induces vascular endothelial growth factor gene transcription in human osteoblast-like cells through the hypoxia- inducible factor-2 alpha.Endocrinology, 2001, 142(2):950-962.
44. Ikeda N, Adachi M, Taki T, et al. prognstic significance of angiogenesis in human pancreatic cancer, Br J Cancer, 1999, 79(9/10):1553-1563.
45. Kurebayashi J, Otsuki T, Kurosumi M, et al. A radicicol derivative, KF58333, inhibits expression of hypoxia-induxible factor-1 alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenograts [J]. Jpn J Cancer Res, 2001, 92(12):1342-1351.
46.胡明均,刘勇,王家宁,等.热休克蛋白90α在血管内皮生长因子165基因治疗大鼠脑梗死中的表达及意义.上海医学[J],2005, 28(3):233-235.
47.廖雪莲,谢晓恬,李本尚,等.血管内皮生长因子体外对人急性白血病细胞株HL-60细胞凋亡及相关基因表达影响的实验研究.中国小儿血液与肿瘤杂[J]. 2006, 11(5):256-260.
48. Ratcliffe PJ. HIF-1αHIF-2α: working alone or together in hypoxia. J clin Invest, 2007, 117(4):862-865.
49. Hopfl G, Ogunshola O and Gassmann M, HIFs and tumors-cavses and consequencces , Am J physiol Regul Integr Comp physiol, 2004, 286(4):R 608-623.
50. Krieg M, Haas R, Brauch H, et al. Up-regultation of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function [J]. Oncogene, 2000,19(48): 5435-5443.
1. Workman P. Pharmacogenomics in cancer drug discovery and development: inhibitors of HSP90 molecular chaperone. Cancer Detect Prew, 2002, 26:405-410.
2. Blagosklonny MV. HSP90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia, 2002, 16:455-462.
3. Wilch WJ. Adenosine AL receptor antagonists in the kidney: effects in fluid-retaining disorders. Curr Opin Pharmacol. 2002 Apr; 2(2):165-170.
4. Kim SA, Yoon JH, et al. Polo-like kinase 1 phosphorlates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress[J]. I Biol Chem. 2005, 280:12653-12657.
5. Morimoto RI. Dynamic remodeling of transcription complexes by molecular chaperones [J]. Cell, 2002, 110:281-284.
6. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy:the story unfolds[J]. Expert Opin Biol Ther, 2002, 2;3-24.
7. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of HSP90 by the stress-regulated cochaperone Ahal [J]. Mol Cell, 2002, 10:1307-1318.
8. Jacques R .Evolution of heat shock Protein and immunity [J]. Dev Comp Immunol, 2003, 27(6-7):449-464.
9. Shu-ling Z, Jun Y, Xiao-kuan C, et al. Regulation of human HSP90 Gene expression [J]. FEBS Letters, 1999, 444(3):130-135.
10. Janzen NK, Kim HL, Figlin RA, et a1. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J]. Urol Clin North Am, 2003, 30(4):843-852.
11. Mickisch G, Carballido J, Hellsten S, et al. Guidelines on renal cell cancer, Eur Urel, 2001, 40(3):252-255.
12.张杰,田波,葛名欢,等.不同热休克蛋白在肾细胞癌组织中的表达及其意义[J].中国组织化学与细胞化学.2003, 3(12):272-275.
13. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res, 1999, 59: 5830-5839.
14. Yan Q, Kamura T, Cai Y, et al. Identification of Elongin C and Skpl sequences that determine Cullin selection [J]. J Biol Chem, 2004, 279(41):43019-43026.
15. Minet E, Mottet D, Michel G. et al. Hypoxia-induced activation of HIF-l: role of HIF- l alpha-HSP90 interaction. FEBS Lett. 1999. 460(2):251-256.
16. Jennifer S. Isaacs, Yun-Jin Jung, Edward G. HSP90 Regulations a von Hippel Lindau-independent Hypoxia-inducible Factor-l-degradaitve Pathway. J Biol Chem. 2002, 277(33):29936-29944.
17. Fluqel D, Gorlach A, Michiels C. et al. Glycogen Synthase Kinase 3 Phosphorylates Hypoxia Inducible Factor-1(alpha) and Mediates Its Destabilizaiton in a VHL Independent Manner. Mol Cell Biol. 2007, 27(9):3253-3265.
18. Jeong SJ, Pise-Masison CA, Radonovich MF, et al. Activated AKT regulatesNF- kappa B activation, p53 inhibition and cell rvival in HTLV-1-transformed cells [J]. Oncogene, 2005, 24(44):6719-6728.
19. Zhang R, Luo R, Miao R, et al. HSP9O-Akt phosphorylates ASK-1 and ASK-1 mediated apaptosis [J]. Oncogene, 2005, 24(24):3954-3963.
20. Sourbier C, Lindner V, Lang H, et a1. The phosphoinositide 3-kinase/Akt pathway:a new target in human renal cell carcinoma therapy. Cancer Res, 2006, 66(10): 5130-5142.
21. Obermann W M, Sondermann H, RUSSO AA, et a1. In vivo function of HSP9O is dependent on ATP binding and ATP hydrolysis. J Cell Biol. 1998. 143:901-910.
22. SCHOLZ GM, HARTSON SD, CARTLEDGE K, et a1. The molecular chaperone HSP90 is required for signal transduction by wild-type Hck and maintenance of its constitutively active counterpart [J]. Cell Growth Differ, 2001, 12(8):409-417.
23. Rinchart J, Adjei AA, Loruso PM, et al. Muticenter phase study of the oral MEK inhibitor, CI-1O40, in patients with advanced non-smal1-cell lung, breast, colon, and pancreatic cancerl [J]. J Clin Oncol, 2004, 22(11):4456-4462.
24. Hahn M, Li W, Yu C, et al. Rapamycin and UCN-0l synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-MEK/ERK, Akt, and JNK signal transduction pathways [J]. Mol Cancer Ther, 2005, 4(3):457-470.
25. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer trement [J]. Nat Rev Drug Discov, 2003, 2:296-313.
26. DAVIES H, BIGNELL GR, COX C, et a1. Mutations of the BRAF gene in human cancer [J]. Nature, 2002, 417(6892):949-954.
27. Schulze A, Lehmann K, Jefieties HB, et al. Analysis of the transcriptional program induced by Raf in epithelial cells [J]. Genes Dev, 2001, 15:981-994.
28. Isaacs JS, Jung YJ, Mimnaugh EG, et al. HSP9O regulates a von Hippel Lindan- independent hypoxia-inducible factor-l alpha-degradative pathway [J]. J Biol Chem, 2002, 277(33):29936-29944.
29.张海波,吴万垠,柴小妹.艾迪注射液联合多西紫杉醇二线方案治疗32例ⅢB/Ⅳ期非小细胞肺癌的临床观察[J].中华肿瘤防治杂志,2006, 13(18):1440.
30. Blagosklonny MV. HSP-90-associated oncoproteins: multiple targetsof geldanamycin and its analogs [J]. Leukemia, 2002, 16:455-462.
31.宫大鑫,何舜发,孙志熙,等. Survivin在肾癌组织和肾癌细胞系中的表达及意义[J].中国医科大学学报, 2008, 37(1):116-118.
32. KANDA N, SENO H, KONDA Y, et a1. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells[J]. Oncogene, 2004, 23(28):4921-4929.
33.余畅,邓华瑜. HSP90与survivin在人乳腺癌细胞中的作用及机制探讨[J].肿瘤, 2007, 10(27):791-794.
34. Oya M, Takayanagi A, Horiguchi A, et a1. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma [J]. Carcinogenesis, 2003, 24(3):377-384.
35. Nayeen MA, Hess ML, Qian YZ, et al. Delayed preconditioning of cultured adult rat cardiac myocytes: role of 70-and-90Kda heat stress proteins .Am [J]. Physiol, 1997, 273:H861-868.
36. Morais C, Pat B, Gobe G, et a1. Pyrrolidine dithiocarbamate exerts antiproliferative and pro-apoptotic effects in renal cell carcinoma cell lines [J]. Nephrol Dial Transplant, 2006, 21(12):3377-3388.
37. Zhao P, Hu Yc, Talbot IC. Expressing patterns of p16 and cDK4 correlated to prognosis in colorectal carcinoma [J]. J. Wodd J Gastroenteml, 2003. 9(10):2202- 2206.
38.史立新,李钢,洪宝发,等.肾细胞癌组织中CDK4、CyclinD1的表达及其意义[J].解放军医学杂志, 2006, 6(31):548-549.
39. Georgakis GV, Li Y, Rassidakis GZ, et al. inhibition of heat shock protein 90 function by 17-allylamio-17-demethoxygeldanamycin inHodgkin’s lymphoma cells down regulates Akt kinase, dephosphorylatesextracellular signal-regulated kinase, and induces cell cycle arrest andcell death [J]. Clin Cancer Res, 2006, 12(2):584-590。
40.邱国战,周洪革,李旭东. p73和p53在肾癌中的表达及其意义.沈阳医学院学报[J]. 2004, 6(2):68-70.
41. Hara T, Noma T, Yamashiro Y, et al. Quantitative analysis of telonerase activtiy and telomerase reverse transcriptase expression in renal cell carcinoma[J]. Urol Res, 2001, 29(1):1-6.
42. Mehle IM, Bacchetti S. A survery of telomerase activity in human cancer J. Eur J Cancer, 1997, 38(5):787-791.